Anest. intenziv. Med. 2020;31(4):172-175 | DOI: 10.36290/aim.2020.035

Hemadsorption therapy in critically ill patients - double blind bet?Review Article

Horák J.^{1, 2}, Chvojka J.^{1, 2}, Tégl V.^{2, 3}, Nalos L.^{2, 4}, Peltanová M.^{2, 3}, Beneš J.^{2, 3}, Matějovič M.^{1, 2}

¹ I. interní klinika, Lékařská fakulta v Plzni, Univerzita Karlova a Fakultní nemocnice Plzeň

² Biomedicínské centrum, Lékařská fakulta v Plzni, Univerzita Karlova

³ Klinika anesteziologie, resuscitace a intenzivní medicíny, Lékařská fakulta v Plzni, Univerzita Karlova a Fakultní nemocnice Plzeň

⁴ Ústav fyziologie, Lékařská fakulta v Plzni, Univerzita Karlova

Recently, the therapeutic approach using the extracorporeal hemadsorption technologies attracted much attention. Effort to affect the patophysiological processess associated with critical illness represents an attractive concept, that penetrates into clinical practice. Here we present the critical opinion on current status of hemadsorption therapy in critical ill patients in the context of published evidence.

Keywords: hemadsorption, sepsis, critical illness, CytoSorb, oXiris.

Received: May 14, 2020; Revised: July 9, 2020; Accepted: August 18, 2020; Prepublished online: August 31, 2020; Published: September 18, 2020  Show citation